These engineered NK cells integrate the high HLA-E binding affinity of the NKG2A ectodomain with the activating signaling potential of the NKG2C endodomain, potentially enabling enhanced and selective cytotoxicity against tumor cells exhibiting elevated HLA-E expression. This evidence concerns the gene KLRC2 and neoplasm.